Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Chiari I malformation: Clinical Characteristics, Symptoms, and Presentations.
General Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
Chiari malformation type 1 (CM-1) is a congenital anomaly associated with herniation of tonsillar pillars due to abnormality in hindbrain. Standard practice in treatment of (CM-1) is surgical decompression or conservative observation. 
We aim to conduct this retrospective study to compare surgery and conservative treatment’s demographics, clinical presentations, and interventions for CM-1 patients in a tertiary hospital in Jordan.  
We reviewed our hospital’s patients’ clinical records, Brain MRI, and surgical assessment notes for CM-1 patients who presented to our hospital for the period between 2000 to 2022.  
We identified 37 patients with (mean age) of (26.5 +/- 19.77) years old and a female predominance n=21 (56.75%). Most patients were incidentally diagnosed or presented without symptoms n=22 (59.45%). Out of the 37 patients identified n=7 (18.9%) underwent surgery while n=30 (81.1%) were treated conservatively. Patients who underwent surgery were older in age compared to those who did not with a (mean age +/- S.D.) of (33.00 years +/- 16.5) and (25.03 +/- 20.40), respectively (p=0.08). Surgery was associated with worsening of symptoms compared to observation 57.14% vs 13.33% (p=0.01). Females were as likely to undergo surgery compared to males 19.04% vs 18.75% (p=0.98). Headache was the initial presentation in n=15 (40.50%) of the patients, other common presentations include: cranial nerve deficits n=20 (54.05%), neck and back pain in n=8 (21.62%), and gait abnormalities n=4 (10.81%). 
Chiari malformation type 1 is a medical condition with a wide array of clinical presentations that is hard to diagnose. Optimum treatment for CM-1 and its association with symptoms alleviation needs further investigation.   
Yazan Samer Al-Zamer (Jordan University of Science and Technology)
Mr. Al-Zamer has nothing to disclose.
Samah Khalil Aburahma, MD (Jordan University S & TFaculty of Medicine) Dr. Aburahma has nothing to disclose.
Ruba Khasawneh (Jordan University of Science and Technology) Dr. Khasawneh has nothing to disclose.
Ethar Hazaimeh, MD Dr. Hazaimeh has nothing to disclose.
Omar Fatehi Jbarah, MD (Jordan University of Science and Technology) Dr. Jbarah has nothing to disclose.